Last reviewed · How we verify
NCT05754541
Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot Study(GRAFT Study)
NA trial testing WeFlow-Tribranch Aortic Arch Stent Graft System in Aortic Aneurysm and Dissection in 20 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Hangzhou Endonom Medtech Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 10 November 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2025 |
| Sites | 4 locations across China |
Drugs / interventions tested
- WeFlow-Tribranch Aortic Arch Stent Graft System
Conditions studied
- Aortic Aneurysm and Dissection — all drugs for Aortic Aneurysm and Dissection →
Sponsor
Hangzhou Endonom Medtech Co., Ltd.
Who can join
Adults 18 to 80, any sex, with Aortic Aneurysm and Dissection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the effect and prognosis of endovascular interventional therapy in high-risk patients with aortic arch dissection and aneurysm
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05754541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Aneurysm and Dissection
Currently open trials in the same condition.
- NCT07438327 — AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation · recruiting
- NCT06336213 — Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients · NA · recruiting
- NCT05434481 — MITAORTA - Role of Mitochondrial Dynamic in Aneurysm and Dissection of Ascending Thoracic Aorta · NA · active not recruiting
- NCT07422129 — Multidisciplinary Analysis by Morphological and Mechanical Evaluation of the Aortic Wall in Patients Undergoing Cardiac · recruiting
Other Hangzhou Endonom Medtech Co., Ltd. trials
Trials by the same sponsor.
- NCT07170332 — ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection · NA · not yet recruiting
- NCT06385379 — Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study) · NA · recruiting
- NCT06062524 — Guo's False Lumen Embolization : The First in Man Study of WeFlow-EndoSeal Aorta Vascular Plug System · NA · recruiting
- NCT05872282 — Percutaneous Endovascular Arch Repair Trial (PEART) Study · NA · unknown
- NCT05179967 — Safety and Efficacy Study of WeFlow-JAAA Stent Graft System for Complex Abdominal Aortic Aneurysm(GREAT Study) · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05754541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Endonom Medtech Co., Ltd.
- Last refreshed: 29 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05754541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing